Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML

“Looking at the entire cohort, we had 23 patients, and composite complete response was seen in 48% of the patient population. It’s important to know that all 23 patients were high risk or adverse risk by European LeukemiaNet 2022 classification.”

Sankalp Arora, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discussed findings from a phase 2 study investigating azacitidine (Vidaza) plus venetoclax (Venclexta) and gilteritinib (Xospata) for the treatment of patients with newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.